Conference Coverage
Conference Coverage
ARNI bests ARB to reduce NT-proBNP in stabilized preserved-EF HF
“Hopefully, these trial data help strengthen clinicians’ resolve to prescribe sacubitril-valsartan to a growing population of vulnerable patients...
Conference Coverage
Care bundle improves outcome in ICH: INTERACT3
“This is a groundbreaking result. It is the first-ever published trial in ICH patients to show a clear benefit on functional outcomes and on...
Conference Coverage
Trientine reduces NT-proBNP up to 8 weeks in HFrEF: TRACER-HF
“It is always exciting to consider new pathways to treat patients with systolic dysfunction, given the residual risk even for patients on...
Conference Coverage
Real-world data validate ESC risk model in NSTE-ACS
A real-world study has potentially validated a risk model put forward by the ESC for management of acute coronary syndromes without persistent ST-...
Conference Coverage
Cut in AFib burden gains traction as gauge of ablation success: PULSED-AF
It’s the first study tying those outcomes to residual AFib burden after ablation achieved using the emerging pulsed-field ablation technology.
Conference Coverage
Earlier anticoagulation safe in stroke with AFib: ELAN
“This trial will change clinical practice in that we can feel much more reassured that starting DOAC treatment early in these patients will not...
Conference Coverage
Half of deaths from homozygous FH occur before age 32 years
“We should do something to prolong the lives of those people,” because the current results are “terrifying.”
Conference Coverage
CardioMEMS boosts QoL, curbs HF hospitalizations: MONITOR-HF
The presentation drew such applause that one chairperson described it as “close to a standing ovation.”
Conference Coverage
Losing weight may bolster AFib ablation’s chances for success: LEAF interim results
“We’re talking about a moderate amount of weight loss. These patients are not going from being obese to being thin. They’re still quite overweight...
Conference Coverage
Novel antibody safe, promising for ATTR in phase 1 trial
“Ultimately, we are going to need to see a phase 3 clinical trial which shows that NI006 – on top of standard-of-care treatment – improves hard...
Conference Coverage
Noninferior to DES, novel bioadaptable stent may improve target vessel physiology
By restoring blood vessel hemodynamics, a novel bioadaptable – as opposed to bioabsorbable – coronary stent might change long-term outcomes,...